| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | NEUTRAL | BUY | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 25.44▼ | 25.22▲ | 25.22▲ | 25.47▲ | 25.23▲ |
| MA10 | 25.02▲ | 24.90▲ | 24.90▲ | 25.10▲ | 26.02▼ |
| MA20 | 25.30▼ | 25.38▼ | 25.39▼ | 25.21▲ | N/A |
| MA50 | 25.71▼ | 25.87▼ | 26.00▼ | 26.15▼ | N/A |
| MA100 | 26.26▼ | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.069▲ | 0.047▲ | 0.056▲ | 0.127▲ | N/A |
| RSI | 47.115▼ | 46.774▼ | 46.557▼ | 50.545▲ | N/A |
| STOCH | 63.301 | 47.995 | 47.995 | 82.468▲ | N/A |
| WILL %R | -45.865 | -53.698 | -53.698 | -23.387▲ | -60.671 |
| CCI | 33.964 | 13.571 | 13.571 | 63.375 | -55.773 |
|
Tuesday, March 08, 2022 08:30 AM
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ...
|
|
Monday, January 03, 2022 11:00 PM
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/07/26 | 25.195 | 25.5154 | 25.195 | 25.5154 | 1,934 |
| 08/07/26 | 25.41 | 25.43 | 25.30 | 25.3378 | 21,066 |
| 07/07/26 | 25.92 | 25.92 | 25.6955 | 25.6955 | 2,227 |
| 06/07/26 | 25.41 | 25.59 | 25.14 | 25.5269 | 10,118 |
| 02/07/26 | 25.30 | 25.34 | 25.0319 | 25.2856 | 4,379 |
| 01/07/26 | 25.31 | 25.51 | 25.17 | 25.4068 | 4,674 |
| 30/06/26 | 24.64 | 24.8221 | 24.63 | 24.8221 | 1,715 |
| 29/06/26 | 24.64 | 24.9291 | 24.64 | 24.863 | 7,608 |
| 26/06/26 | 24.31 | 24.56 | 24.2749 | 24.2749 | 85,742 |
| 25/06/26 | 24.38 | 24.39 | 24.19 | 24.2648 | 24,284 |
|
|
||||
|
|
||||
|
|